Genentech's Giredestrant Combo Fails Primary Endpoint in Breast Cancer Trial
Event summary
- Genentech's Phase III persevERA study evaluating giredestrant in combination with palbociclib did not meet its primary endpoint of improved progression-free survival (PFS) in first-line treatment for ER-positive, HER2-negative metastatic breast cancer.
- The trial enrolled 992 patients globally and compared the giredestrant/palbociclib combination to letrozole plus palbociclib.
- Despite the primary endpoint miss, Genentech reported a numerical improvement in PFS and maintains confidence in giredestrant's potential.
- The FDA has accepted a New Drug Application (NDA) for giredestrant based on data from the evERA trial, and lidERA data will be submitted shortly.
The big picture
The failure of persevERA highlights the ongoing challenges in developing effective treatments for ER-positive breast cancer, a market representing a significant portion of the oncology landscape. While giredestrant shows promise, its commercial success hinges on identifying patient populations where it delivers a clear benefit, and navigating regulatory hurdles. This outcome underscores the inherent risk in late-stage clinical development, even for companies with deep pockets like Roche.
What we're watching
- Clinical Focus
- Genentech's pivot towards adjuvant settings for giredestrant, while abandoning first-line combination, suggests a reassessment of optimal application and may impact future development costs.
- Regulatory Risk
- The FDA's acceptance of the NDA based on evERA data introduces regulatory risk; the lidERA submission and subsequent review will be critical for broader market access.
- Pipeline Impact
- The pionERA trial readout in 2027 will be crucial in determining the viability of giredestrant in endocrine-resistant breast cancer, potentially impacting the entire development program.
Related topics